Karyopharm Therapeutics
US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.
Founded
2008US-based Karyopharm Therapeutics offers oncology-focused pharmaceutical solutions, specializing in multiple myeloma treatments.
Founded in Newton, United States, Karyopharm Therapeutics is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of medicines aimed at improving the lives of patients with cancer and other major diseases. The company specializes in oncology-focused solutions, particularly in the treatment of multiple myeloma, offering both single-agent and combination therapies. Karyopharm serves patients primarily in the United States, Germany, and Israel.
Notable figures associated with Karyopharm include its leadership team and key investors who have supported its mission to advance cancer treatment. The company has achieved significant milestones, including the successful development and approval of several therapeutic agents. Karyopharm's impact is evident in its contribution to improving patient outcomes and advancing the field of oncology through innovative pharmaceutical solutions.
Companies similar to Karyopharm Therapeutics include Kymera Therapeutics, Deciphera Pharmaceuticals, Traws Pharma and K36 Therapeutics.
Karyopharm Therapeutics was founded in 2008.
Karyopharm Therapeutics' headquarters is located in Newton, MA, US.
Karyopharm Therapeutics' most recent funding round was for $165M (USD) in December 2022.
As of Dec 5, 2022, Karyopharm Therapeutics has disclosed funding of $546.7M (USD). Undisclosed round amounts are excluded.
Karyopharm Therapeutics has 385 employees as of Feb 6, 2024.
K36 Therapeutics
k36tx.com
